Roche invested $20 million in C4 Therapeutics to advance antibody-targeted protein degraders (ATPDs).
The deal includes potential milestone payments up to $150 million and royalties on future sales.
ATPDs combine targeted protein degradation with antibody delivery for enhanced precision in oncology.
Announcement made in early 2026, highlighting Roche's commitment to next-gen degradation therapies.
C4T's platform aims to degrade disease-causing proteins more effectively than traditional PROTACs.